Drug Type Antibody drug conjugate (ADC) |
Synonyms CEACAM5-TOPO1 ADC (Bristol Myers Squibb), BMS 986490, BMS986490 |
Target |
Action modulators, inhibitors |
Mechanism CEACAM5 modulators(Carcinoembryonic antigen related cell adhesion molecule 5 modulators), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | United States | 12 Feb 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | Australia | 12 Feb 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | Canada | 12 Feb 2025 |






